- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Placebo, Benralizumab 100 mg
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Marietta, Georgia • Normal, Illinois + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- MEDI-563, Placebo Comp., Placebo
- Drug · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Benralizumab, Placebo and Benralizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
- Conditions
- Nasal Polyposis
- Interventions
- Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more
- Conditions
- Asthma
- Interventions
- Placebo, Benralizumab
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 2,681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 110
- States / cities
- Foley, Alabama • Huntsville, Alabama • Mobile, Alabama + 107 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Benralizumab, Matching placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 17 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 84
- States / cities
- Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more
- Conditions
- Asthma
- Interventions
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
- Biological · Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
- Conditions
- Eosinophilic Granulomatous Vasculitis
- Interventions
- Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more